ALKS Share Price

Open 56.28 Change Price %
High 58.34 1 Day 2.06 3.66
Low 55.92 1 Week 1.44 2.53
Close 58.27 1 Month 4.30 7.97
Volume 689667 1 Year -13.46 -18.76
52 Week High 80.71
52 Week Low 27.14
ALKS Important Levels
Resistance 2 60.51
Resistance 1 59.59
Pivot 57.51
Support 1 56.95
Support 2 56.03
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
WRES 0.09 0.00%
SIRI 4.41 1.85%
QQQ 116.87 0.23%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
ECTE 0.14 40.00%
BNSO 3.57 31.25%
FRAN 20.01 28.76%
FRAN 20.01 28.76%
FRAN 20.01 28.76%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
CRDS 5.45 25.87%
OTT 2.39 25.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
IMRS 0.02 -33.33%
More..

Alkermes plc (NASDAQ: ALKS)

ALKS Technical Analysis 4
As on 6th Dec 2016 ALKS Share Price closed @ 58.27 and we RECOMMEND Buy for LONG-TERM with Stoploss of 44.59 & Strong Buy for SHORT-TERM with Stoploss of 51.96 we also expect STOCK to react on Following IMPORTANT LEVELS.
ALKS Target for December
1st Target up-side 62.68
2nd Target up-side 66.79
3rd Target up-side 70.89
1st Target down-side 50.98
2nd Target down-side 46.87
3rd Target down-side 42.77
ALKS Other Details
Segment EQ
Market Capital 2719078400.00
Sector Healthcare
Industry Drug Delivery
Offical website http://www.alkermes.com
ALKS Address
ALKS
Connaught House
1 Burlington Road
Dublin, 4
Ireland
Phone: 353 1 772 8000
ALKS Latest News
Alkermes plc (NASDAQ:ALKS) Median Target At $54   Markets Daily   - 16th Jun 16
Alkermes plc (NASDAQ:ALKS) Average Stock Rating Recap   The Post   - 16th Jun 16
Alkermes Plc (NASDAQ:ALKS) Given Average Recommendation of "Hold" by Analysts   The Cerbat Gem   - 15th Jun 16
Alkermes plc (NASDAQ:ALKS) Comprehensive Income Is $-3.795   Enterprise Leader   - 14th Jun 16
Analyst Suggestions Roundup: Alkermes plc (NASDAQ:ALKS), Norwegian Cruise Line ...   Beacon Chronicle   - 13th Jun 16
How Many Alkermes Plc (NASDAQ:ALKS)'s Analysts Are Bearish?   Franklin Independent   - 10th Jun 16
Analysts: Alkermes Plc (NASDAQ:ALKS)   CWRU Observer   - 08th Jun 16
Alkermes plc (ALKS) Commences ALKS 4230 Phase 1   StreetInsider.com   - 25th May 16
Alkermes plc (ALKS) Offers Prelim. Data from ALKS 7119 Phase 1; Plans ...   StreetInsider.com   - 28th Apr 16
Will Alkermes Plc Recover From High Profile Failures?   Business Finance News   - 22nd Jan 16
Interactive Technical Analysis Chart Alkermes plc ( ALKS NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Alkermes plc
ALKS Business Profile
Alkermes Public Limited Company, incorporated on May 4, 2011, is an integrated, global biopharmaceutical company. The Company has a portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. The Company manufactures RISPERDAL CONSTA, VIVITROL and polymer for BYDUREON in its Wilmington, Ohio facility. The Company operates PERDAL CONSTA lines and one VIVITROL line at commercial scale. The Company manufactures AMPYRA/FAMPYRA, RAPAMUNE and other products in its Athlone, Ireland facility. It manufactures FOCALIN XR, RITALIN LA, AVINZA, VERAPAMIL and other products in its Gainesville, Georgia facility. The Company’s RISPERDAL CONSTA (risperidone long-acting injection) and INVEGA SUSTENNA/XEPLION (paliperidone palmitate extended-release injectable suspension) are long-acting atypical antipsychotics that incorporate its technologies. RISPERDAL CONSTA uses its polymer-based microsphere injectable extended-release technology to deliver and maintain therapeutic medication levels in the body through just one injection every two weeks. RISPERDAL CONSTA is manufactured by the Company and is marketed and sold by Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica International, a division of Cilag International AG (Janssen) around the globe. INVEGA SUSTENNA uses its nanoparticle injectable extended-release technology to increase the rate of dissolution and enable the formulation of an aqueous suspension for once-monthly intramuscular administration.